CB Oncology Partners (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Sep. 02, 2017
Condensed Income Statement Information [Abstract]
Patient revenue		$ 0	$ 0	$ 0	$ 1,061,000
Net (loss) income		(378,000)	(352,000)	(2,167,000)	(677,000)
USNC's equity in (loss) income		(156,000)	(77,000)	(1,287,000)	(351,000)
Condensed Balance Sheet Information [Abstract]
Current assets		703,000		703,000		$ 2,243,000
TOTAL ASSETS		1,209,000		1,209,000		3,688,000
Current liabilities		336,000		336,000		626,000
Deficit		862,000		862,000		3,028,000
TOTAL LIABILITIES AND EQUITY		1,209,000		1,209,000		3,688,000
CB Oncology Partners LLC [Member]
Condensed Income Statement Information [Abstract]
Patient revenue		482,000	550,000	1,507,000	1,591,000
Net (loss) income		(158,000)	(23,000)	(387,000)	69,000
Condensed Balance Sheet Information [Abstract]
Current assets		444,000		444,000		400,000
Noncurrent assets		3,209,000		3,209,000		3,667,000
TOTAL ASSETS		3,653,000		3,653,000		4,067,000
Current liabilities		3,598,000		3,598,000		3,472,000
Noncurrent liabilities		2,968,000		2,968,000		3,121,000
Deficit		(2,913,000)		(2,913,000)		(2,526,000)
TOTAL LIABILITIES AND EQUITY		3,653,000		3,653,000		$ 4,067,000
CB Oncology Partners LLC [Member]
CB Oncology Partners [Abstract]
Ownership percentage	28.58%						24.00%
Capital called from members	$ 500,000
Advances converted into equity	121,000
Contribution in cash	$ 212,000
Outstanding amount		2,716,000		2,716,000
Condensed Income Statement Information [Abstract]
USNC's equity in (loss) income		$ (45,000)	$ (7,000)	$ (111,000)	$ 20,000